The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
Official Title: A Retrospective Observational Study to Evaluate the Clinical Outcomes and Routine Management of Patients With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
Study ID: NCT03582098
Brief Summary: The primary objective of this study is to evaluate the effectiveness of idelalisib and rituximab in adults with chronic lymphocytic leukaemia (CLL) in a real world setting
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
St James Hospital, Dublin, , Ireland
NHS Grampian, Aberdeen, , United Kingdom
University Hospital of Wales, Cardiff, , United Kingdom
Cheltenham General Hospital, Cheltenham, , United Kingdom
London Northwest University NHS Trust, Eastcote, , United Kingdom
Medway Maritime Hospital, Gillingham, , United Kingdom
Queen Alexandra Hospital, Harrow, , United Kingdom
King's College Hospital NHS Foundation Trust, London, , United Kingdom
Milton Keynes University Hospital, Milton Keynes, , United Kingdom
Oxford University Hospitals NHS Trust, Oxford, , United Kingdom
Whiston Hospital - St Helens And Knowsley Teaching Hospitals NHS Trust, Prescot, , United Kingdom
Southend University Hospital NHS Foundation Trust, Southend-On-Sea, , United Kingdom
Royal Marsden Hospital, Sutton, , United Kingdom
Singleton Hospital, Swansea, , United Kingdom
Royal Cornwall Hospital, Truro, , United Kingdom
Worcestershire Royal Hospital, Worcester, , United Kingdom
Name: Gilead Study Director
Affiliation: Gilead Sciences
Role: STUDY_DIRECTOR